article thumbnail

STAT+: Truveta enlists health systems, drugmakers to launch ambitious new genomic database

STAT

The genetic data, cross-referenced with the patients’ de-identified medical records, will be available for purchase for researchers and life sciences companies. Pharmaceutical company Regeneron has invested $119.5

article thumbnail

STAT+: Express Scripts overcharged postal workers by $45 million, audit says

STAT

The report , which was released in March but received little if any public attention, examined drug spending between 2016 and 2021 within the health plan that covers more than 200,000 unionized mail carriers and post office workers, as well as retirees.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: U.K. pharma increasingly violates voluntary industry marketing codes, and probes are taking longer

STAT

Pharmaceutical companies in the U.K. Between 2004 to 2021, the Prescription Medicines Code of Practice Authority, a self-regulatory body overseen by the Association of the British Pharmaceutical Industry, ruled on more than 1,100 cases involving nearly 160 companies where there was a breach of the industry code.

article thumbnail

STAT+: Icon acquires HumanFirst to boost support for digital tools in clinical trials

STAT

Following the acquisition, HumanFirst will be another offering for Icon, which earned $8 billion last year running clinical trials for pharmaceutical companies and other related services.

article thumbnail

Entries now open for the Patient Partnership Index 2021

Pharma Times

The Patient Partnership Index 2021 provides a unique opportunity for UK and global pharmaceutical companies to showcase, benchmark and measure the quality and impact of their advocacy with patient groups

article thumbnail

Optimizing Your Drug Patent Strategy: A Comprehensive Guide for Pharmaceutical Companies

Drug Patent Watch

Drug patents are a form of intellectual property protection that grants pharmaceutical companies exclusive rights to manufacture, sell, and profit from their innovations for a set period. This exclusivity is the lifeblood of the industry, allowing companies to recoup their substantial R&D investments and fund future discoveries.

article thumbnail

STAT+: More drugmakers are expanding access in poorer countries, but progress continues to lag overall

STAT

For the first time, many of the world’s largest pharmaceutical companies are taking concrete steps to widen access to their medicines in low and middle-income countries, but the poorest countries continue to be disproportionately overlooked, according to a new analysis. Continue to STAT+ to read the full story…